Publicaciones en colaboración con investigadores/as de Centro de Investigación Médica Aplicada (22)

2024

  1. Profile of plasma microRNAs as a potential biomarker of Wilson’s disease

    Journal of Gastroenterology, Vol. 59, Núm. 10, pp. 921-931

2022

  1. High value of 64Cu as a tool to evaluate the restoration of physiological copper excretion after gene therapy in Wilson's disease

    Molecular Therapy - Methods and Clinical Development, Vol. 26, pp. 98-106

2019

  1. Liver Expression of a MiniATP7B Gene Results in Long-Term Restoration of Copper Homeostasis in a Wilson Disease Model in Mice

    Hepatology, Vol. 70, Núm. 1, pp. 108-126

2018

  1. Brain copper storage after genetic long-term correction in a mouse model of Wilson disease

    Neurology: Genetics, Vol. 4, Núm. 3

  2. Visualization of the therapeutic efficacy of a gene correction approach in Wilson's disease by laser-ablation inductively coupled mass spectrometry

    Journal of Hepatology

2013

  1. T cell costimulation with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes

    Journal of Immunology, Vol. 190, Núm. 12, pp. 6694-6706

2012

  1. CD137 on inflamed lymphatic endothelial cells enhances CCL21-guided migration of dendritic cells

    FASEB Journal, Vol. 26, Núm. 8, pp. 3380-3392

  2. Liver Gene Transfer of Interkeukin-15 Constructs That Become Part of Circulating High Density Lipoproteins for Immunotherapy

    PLoS ONE, Vol. 7, Núm. 12

2010

  1. Proliferating NK cells in response to IL-15 do not upregulate surface B220 in vivo

    Gene Therapy

2009

  1. In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb

    European Journal of Immunology, Vol. 39, Núm. 9, pp. 2424-2436

2008

  1. Interleukin-15 liver gene transfer increases the number and function of IKDCs and NK cells

    Gene Therapy, Vol. 15, Núm. 7, pp. 473-483

  2. Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies

    Trends in Pharmacological Sciences, Vol. 29, Núm. 8, pp. 383-390

  3. Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma

    Clinical Cancer Research, Vol. 14, Núm. 21, pp. 6895-6906

2007

  1. Absence of surface expression of CD137 (4-1BB) on Myeloid-derived suppressor cells

    Inmunologia, Vol. 26, Núm. 3, pp. 121-126

  2. Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer

    Expert Opinion on Biological Therapy, Vol. 7, Núm. 5, pp. 599-615

  3. Immunotherapy and immunoescape in colorectal cancer

    World Journal of Gastroenterology, Vol. 13, Núm. 44, pp. 5822-5831

  4. The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFNγ

    International Journal of Cancer, Vol. 121, Núm. 6, pp. 1282-1295

2006

  1. Immunogenic cell death and cross-priming are reaching the clinical immunotherapy arena

    Clinical Cancer Research

  2. Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma

    Cancer Research, Vol. 66, Núm. 4, pp. 2442-2450

2005

  1. Critical appraisal of the current status of dendritic cell based therapy

    Inmunologia, Vol. 24, Núm. 1, pp. 23-32